SIRT6 and hepatocellular carcinoma: The researchers found that MDL-800 inhibits the proliferation of HCC cells via SIRT6-driven cell-cycle arrest, and they also suggested that MDL-800 suppresses proliferation and enhances osimertinib therapy in NSCLC [37, 63].